Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m2 and at 25 mg/m2 Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisolone; Prednisone
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROSELICA
- Sponsors Sanofi
- 12 Sep 2017 Post hoc subgroup analysis results presented at the 42nd European Society for Medical Oncology Congress
- 15 Aug 2017 Primary endpoint [Overall Survival (OS)] has been met, according to the results published in the Journal of Clinical Oncology.
- 15 Aug 2017 Results published in the Journal of Clinical Oncology.